Nabla

AI that restores care

Paris, France

Nabla offers a SaaS-based ambient AI assistant for clinical documentation, leveraging proprietary Large Language Models (LLM) and Speech-to-Text (STT) technologies. The platform is expanding into agentic AI to provide autonomous assistance within EHR workflows.

Nabla hero image

✓Source: HealthTech Alpha by Galen Growth

Shareable draft

Check out Nabla on @MedStartr Today Nabla offers a SaaS-based ambient AI assistant for clinical documentation, leveraging proprietary Large Language Models (LLM) and Speech-to-Text (STT) technologies. The platform is expanding into agentic AI to provide autonomous assistance within EHR workflows. #MentalBehavioralHealth #ClinicalDocumentation #AIML #MedMo #MedStartrVentures

https://www.medstartr.ai/s/CAlmUdbD_hk

Get Involved in Nabla

How We Help

Problem Statement

Clinicians face a significant burden and inefficiency in clinical documentation.

Core Technology

Proprietary Large Language Models (LLM) and Speech-to-Text (STT) technologies are utilized, with a strategic move towards agentic AI for autonomous EHR interactions.

Key Differentiators

Multi-language support in 35+ languages; Supports 50+ medical specialties; EHR integration with Epic, Cerner, athenahealth, Oracle, NextGen, Greenway Health, and Opus

Clinical Focus

medical specialties

Company Info

Business Model: B2B SaaS
Founded: 2018
Total Funding: Only accessible to MedStartr community members. Join now
Only accessible to MedStartr community members.
Join now
Website: www.nabla.com/

Disease Areas

Mental Health

Technologies

LLMsAmbient AIAgentic AIGenerative AIMachine LearningNLPSpeech-to-TextAI & Machine Learning

Clinical & IP

🔬

Clinical Validation

Peer-reviewed RCT in PMC published 2025 (238 physicians, 14 specialties): 41-second reduction in documentation time-in-note, significant burnout reduction. Real-world data confirms 15-point patient satisfaction increase. HIPAA/GDPR compliant, SOC 2 Type 2, ISO 27001 certified.

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of Nabla?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.